We are live on ! Find out more
Marshall Wace

Marshall Wace Portfolio holdings

AUM $100B
1-Year Est. Return 35.1%
This Fund
S&P 500
This Quarter Est. Return
-1.4%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$45.6B
AUM Growth
-$2.97B
Cap. Flow
-$1.56B
Cap. Flow %
-3.42%
Top 10 Hldgs %
10.17%
Holding
4,085
New
718
Increased
950
Reduced
874
Closed
814

Top Buys

Rank Stock Value
1
JPM icon
JPMorgan Chase
JPM
+$352M
2
KR icon
Kroger
KR
+$279M
3
T icon
AT&T
T
+$235M
4
INTC icon
Intel
INTC
+$217M
5
EW icon
Edwards Lifesciences
EW
+$212M

Sector Composition

Rank Sector Weight
1 Financials 19.08%
2 Technology 16.14%
3 Healthcare 15.45%
4 Consumer Discretionary 9.74%
5 Consumer Staples 5.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CIFRW
3201
CALL
DELISTED
Cipher Mining Warrant
CIFRW
$60K ﹤0.01%
48,720
OXY icon
3202
CALL
Occidental Petroleum
OXY
$54.6B
$60K ﹤0.01%
1,000
-15,100
-94% -$967K
PETWW
3203
CALL
DELISTED
Wag! Group Co Warrant
PETWW
$60K ﹤0.01%
29,388
DS
3204
DELISTED
Drive Shack Inc.
DS
$59K ﹤0.01%
+94,773
New +$113K
BCLI
3205
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$58K ﹤0.01%
+868
New +$43.5K
CTMX icon
3206
CytomX Therapeutics
CTMX
$708M
$58K ﹤0.01%
40,021
-24,123
-38% -$37.1K
CUE icon
3207
Cue Biopharma
CUE
$137M
$58K ﹤0.01%
874
-925
-51% -$79.6K
SUPV
3208
Grupo Supervielle
SUPV
$857M
$58K ﹤0.01%
+33,174
New +$56K
EMAN
3209
DELISTED
eMagin Corporation
EMAN
$58K ﹤0.01%
97,609
-237,494
-71% -$176K
PRQR icon
3210
ProQR Therapeutics
PRQR
$244M
$55K ﹤0.01%
73,430
-97,742
-57% -$78.5K
NGCAW
3211
CALL
DELISTED
NextGen Acquisition Corp. II Warrant
NGCAW
$55K ﹤0.01%
18,029
-344,144
-95% -$1.05M
GRABW icon
3212
CALL
Grab Holdings Warrant
GRABW
$520K
$52K ﹤0.01%
19,993
EGLX
3213
DELISTED
Enthusiast Gaming Holdings Inc. Common Stock
EGLX
$51K ﹤0.01%
57,640
-1,400
-2% -$2.15K
IGV icon
3214
CALL
iShares Expanded Tech-Software Sector ETF
IGV
$12.2B
$50K ﹤0.01%
+1,000
New +$56.8K
LCTX icon
3215
Lineage Cell Therapeutics
LCTX
$257M
$50K ﹤0.01%
+43,827
New +$64.4K
QTTB icon
3216
Q32 Bio
QTTB
$452M
$48K ﹤0.01%
1,676
+482
+40% +$19.7K
OTMOW
3217
CALL
DELISTED
Otonomo Technologies Ltd. Warrant
OTMOW
$48K ﹤0.01%
171,149
-3,713
-2% -$243
ACTG icon
3218
Acacia Research
ACTG
$447M
$47K ﹤0.01%
11,711
+1,711
+17% +$7.9K
XNET
3219
Xunlei
XNET
$369M
$46K ﹤0.01%
33,276
-43,769
-57% -$69.1K
HOUR icon
3220
Hour Loop
HOUR
$63.3M
$45K ﹤0.01%
17,219
-5,758
-25% -$17.6K
SIEN
3221
DELISTED
Sientra, Inc.
SIEN
$43K ﹤0.01%
6,718
-22,146
-77% -$176K
RFL icon
3222
Rafael Holdings
RFL
$119M
$41K ﹤0.01%
23,233
-136,064
-85% -$287K
ALPP
3223
DELISTED
Alpine 4 Holdings Inc
ALPP
$41K ﹤0.01%
+9,188
New +$53.6K
CENN icon
3224
Cenntro
CENN
$8.46M
$40K ﹤0.01%
+65
New +$55.7K
DIS icon
3225
CALL
Walt Disney
DIS
$168B
$38K ﹤0.01%
400
-353,900
-100% -$37.9M

Similar funds

Marshall Wace's Q3 2022 Portfolio in Review

As of Q3 2022, Marshall Wace held 4,085 positions worth $45.6B, down 6.1% from $48.6B the previous quarter. Its ten largest holdings account for 10% of the portfolio.

Marshall Wace withdrew a net $1.56B in Q3 2022, closing 814 positions and reducing 874 holdings. Its most notable exit was General Dynamics, an estimated $122M position sold in full.

By sector, the portfolio is most concentrated in Financials at 19% of assets, up from 17% a quarter earlier, followed by Technology and Healthcare.

Against the trend, Marshall Wace opened a new position in Albertsons Companies worth $84.6M.

  • Marshall Wace's largest Q3 2022 buy was Albertsons Companies: 3,404,097 shares worth $84.6M.
  • Marshall Wace added most to JPMorgan Chase in Q3 2022, an estimated $352M increase.
  • Marshall Wace's biggest Q3 2022 reduction was UnitedHealth, cutting an estimated $461M.
  • Marshall Wace fully exited General Dynamics in Q3 2022, selling an estimated $122M.
  • Marshall Wace's ten largest holdings make up 10% of its $45.6B portfolio in Q3 2022.
  • Marshall Wace opened 718 new positions and closed 814 in Q3 2022.
  • Marshall Wace's portfolio value fell 6.1% quarter-over-quarter to $45.6B.

Based on Marshall Wace's 13F filing for Q3 2022, filed 14 Nov 2022.